Inhibitors of lipogenic enzymes as a potential therapy against cancer

Publication date

2020-09-04T10:35:20Z

2020-09-04T10:35:20Z

2020

2020-09-04T10:35:21Z

Abstract

Cancer cells rely on several metabolic pathways such as lipid metabolism to meet the increase in energy demand, cell division, and growth and successfully adapt to challenging environments. Fatty acid synthesis is therefore commonly enhanced in many cancer cell lines. Thus, relevant efforts are being made by the scientific community to inhibit the enzymes involved in lipid metabolism to disrupt cancer cell proliferation. We review the rapidly expanding body of inhibitors that target lipid metabolism, their side effects, and current status in clinical trials as potential therapeutic approaches against cancer. We focus on their molecular, biochemical and structural properties, selectivity and effectiveness and discuss their potential role as antitumor drugs. Keywords: cancer drugs; lipid metabolism; lipogenic enzyme inhibitors.

Document Type

Article


Submitted version

Language

English

Publisher

The Federation of American Society of Experimental Biology

Related items

Versió preprint del document publicat a: https://doi.org/10.1096/fj.202000705R

The FASEB Journal , 2020, vol. 34, num. 9, p. 11355-11381

https://doi.org/10.1096/fj.202000705R

Recommended citation

This citation was generated automatically.

Rights

(c) The Federation of American Society of Experimental Biology, 2020

This item appears in the following Collection(s)